Melanotan 1 vs Thymagen
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticSexual Health & Libido
Melanotan 1Immune Support
Thymagen- Summary
- Melanotan 1 (Afamelanotide) is a synthetic analog of α-MSH that selectively stimulates melanogenesis (tanning) through MC1R activation. It provides UV-independent skin pigmentation and is FDA/EMA-approved under the name SCENESSE for erythropoietic protoporphyria (EPP) and vitiligo.
- Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
- Half-Life
- ~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.5–1 mg
- 10 mg per day
- Frequency
- Daily until desired color achieved, then maintenance
- Daily for 10–30 days
- Key Benefits
- Induces skin pigmentation/tanning without UV exposure
- Provides photoprotection in photosensitivity conditions (EPP)
- FDA-approved for erythropoietic protoporphyria (SCENESSE)
- Approved in EU for EPP treatment
- Anti-inflammatory via MC1R
- Mild libido enhancement
- Potential skin cancer prevention through melanin protection
- Supports thymic epithelial cell function and T-cell maturation
- May partially restore thymic output reduced by age-related atrophy
- Normalizes T-lymphocyte subpopulation balance
- Supports immune recovery after illness, surgery, or chemotherapy
- Anti-aging effects on thymic tissue
- Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
- May improve vaccine responsiveness in older individuals
- Side Effects
- Nausea (especially at higher doses)
- Facial flushing
- Fatigue
- Injection site reactions
- +3 more
- Generally well tolerated
- Mild injection site reactions
- No significant immunological adverse events reported
- Stacks With
- —
- —